It is our immune system that prevents and destroys disease

The first research was done in 1990 by Dr Yamamoto in Philadelphia; and since then 59 research papers have been published by 142 scientists proving that GcMAF is a vital part of the immune system. Chronic diseases succeed by preventing production of your own GcMAF, which collapses your immune system. When administered externally, GcMAF rebuilds the immune system, and the immune system then eradicates early stage cancer and other diseases.

How does GcMAF work?

In a healthy person your GcMAF acts as a "director" of the immune system. But viruses and malignant cells like cancer send out an enzyme called Nagalase that prevents production of the body's GcMAF: that neutralises the immune system. So diseases become chronic, and cancer cells grow unchecked.

To reverse this, GcMAF is extracted and isolate, and it is one dose a week for typically 24 weeks for many diseases and early cancers, a year for later stage cancers.

One week's GcMAF looks like a small raindrop. Its perfectly sterile, and a most ethical course for doctors.

GcMAF simply replaces the part of the immune system that is missing.

Doctors have had successes with many common cancers including prostate and breast, but pancreatic, leukemia and melanoma too.  GcMAF has also been successful with chronic inflammation, bacterial and viral infections, Autism, Chronic Herpes, Chronic Acne, CFS, XMRV, Lyme disease, AIDS, HIV, Fibromyalgia, Osteoporosis, Hodgkin’s,  MS, Parkinson’s, and various types of Immune dysfunction. In its role of immune system regulator, research shows GcMAF can reverse diseases that attack the immune system like Lupus and Arthritis.

Clinics and doctors who have done their own research on it, are invited to respond. We ask for a copy of diagnostic information and update reports from a physician during and after treatments, to help build the case that GcMAF is effective for various illnesses, which will help to make it available to the public. Participants are free to stop at any time.

We are a main supplier for research universities, and 300 cancer clinics and doctors, with over 4,000 participants, and we are the only one who tests for activity, which can only be done with live cell assays like these:

Here is a time lapse video of the 8th assay we do in our laboratory - GcMAF activates macrophages that eat cancers cells. We are probably the only people in the world with this technology.

On the left, click the Video: cancer cells destroyed, to see what happens to cancer cells when GcMAF is added without macrophages. This again is a world first, and again it has been done in our laboratory. Within just 4 weeks a research abstract paper on our results has already been accepted for publication at this year's Immunology Conference in California.

What have we learned?

The many scientists who have published papers on trials of GcMAF selected those in the early stages of cancer and HIV, and reported nearly 100 percent success, with no recurrence after many years. They did not attempt trials on people with large tumours.

Our doctors' trials are quite different: many people are over 50, some over 80, with advanced or terminal cancers, with significant tumour mass.

GcMAF appears to be successful at rebuilding the immune system in around three weeks in the vast majority - probably over 80%. Remember the half life of GcMAF is only one week - you have to keep taking it until your disease has gone, or the immune system gets shut down again. In responders (about 80%) nagalase comes down at the rate of 10-40% every 8 weeks.

The immune system should be given 8 weeks for chronic herpes/acne. Allow 24 weeks of GcMAF plus for: Autism (85% respond), CFS, HIV, XMRV, Lyme (15% respond, most appear to have the VDR gene blocked and the viruses conceal themselves with biofilms) and stage 1 to 2 cancer, (80% respond). Late stage cancer, perhaps 20% responders, takes a year to 18 months. Remember everyone responds differently. We can't say how an individual will respond.

The more minor the disease, the easier it is for GcMAF and the immune system to eradicate. GcMAF needs normal levels of vitamin D to function strongly. But even in low responders, GcMAF usually appears to stop the advance of cancer.

Doctors have probably proved GcMAF can work for people up to age 90, with terminal stage 4 cancer, and can destroy large tumour mass.

If blood is taken for monocyte counts, relevant markers and vitamin D levels, and again for a nagalase test at the beginning,  the next test should show after three weeks that the immune system is back to full strength, and after 8 weeks significantly falling nagalase will indicate the disease is losing its grip. Don't stop the GcMAF until nagalase gets below 0.62 nmol/min/mg, when it loses the ability to prevent the body producing its own GcMAF, and then ours is no longer needed.